Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps

Area of Science:

• Pediatric dermatology
• Immunology
• Pharmacology

Background:

• Biological therapies, such as dupilumab and tralokinumab, are increasingly vital for treating moderate-to-severe atopic dermatitis (AD) in children.
• Dupilumab is the first biologic approved for pediatric AD patients, now including those aged six months to five years.

Purpose of the Study:

• To discuss current practical challenges and knowledge gaps concerning the implementation of biological treatments for infants and preschoolers (under six years) with moderate-to-severe atopic dermatitis.
• To address the unmet need for effective and safe treatment options in this vulnerable population.

Main Methods:

• Review of current literature and clinical guidelines on biological treatments for pediatric atopic dermatitis.
• Analysis of practical aspects including treatment initiation, discontinuation, and long-term administration of subcutaneous injections.
• Identification of knowledge gaps regarding long-term effects, impact on comorbidities, and live-attenuated vaccinations.

Main Results:

• Limited data exist on the practical implementation of biologicals in infants and preschoolers for AD.
• Knowledge gaps persist regarding long-term safety, effects on comorbidities, and impact on live-attenuated vaccinations.
• Potential challenges may arise with the introduction of biologicals for AD starting at six months of age.

Conclusions:

• Further research and practical guidance are needed to optimize the use of biologicals in infants and preschoolers with AD.
• Addressing implementation challenges is crucial for safe and effective biological therapy in this age group.
• Understanding long-term outcomes and safety profiles is essential for widespread adoption.